82776-24-7

Basic information

• Product Name: 3-Pyridinecarbonyl chloride, 2,4-dimethyl- (9CI)
• Synonyms: 3-Pyridinecarbonyl chloride, 2,4-dimethyl- (9CI);2,4-diMethylnicotinoyl chloride
• CAS NO: 82776-24-7
• Molecular Formula: C₈H₈ClNO
• Molecular Weight: 169.60822
• Product Categories: ACIDHALIDE
• Mol File: 82776-24-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinecarbonyl chloride, 2,4-dimethyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinecarbonyl chloride, 2,4-dimethyl- (9CI)(82776-24-7)
• EPA Substance Registry System: 3-Pyridinecarbonyl chloride, 2,4-dimethyl- (9CI)(82776-24-7)

Safety Data

• Hazardous Substances Data: 82776-24-7(Hazardous Substances Data)

Upstream product

• 133897-06-0 2,4-dimethylpyridine-3-carboxylic acid hydrochloride 
• 55314-30-2 2,4-dimethylnicotinic acid 

Downstream Products

• 103133-97-7 3-(N-Methyl-N-(R)-α-methylbenzylcarbamoyl)-2,4-dimethylpyridine 
• 1076692-18-6 2,4-dimethyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]nicotinanilide monohydrochloride 
• 101948-10-1 N-benzyl-N-methyl-1,2,4-trimethyl-3-carbamoyl pyridinium iodide 

Relevant articles and documents

Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4′-[(trifluoromethyl)pyrazol-1-yl]carboxanilides

From a series of 4'-[(trifluoromethyl)pyrazol-1-yl]carboxanilides derived from 4-methyl-4'-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-1,2,3-thiadiazole-5-carboxanilide, one inhibited thapsigargin-induced Ca2+ influx in Jurkat T cells (IC50 = 77 nM) and exhibited high selectivity for the CRAC channel over the VOC channel (index: >130). Another acted as an inhibitor for both T lymphocyte activation-induced diseases and ovalbumin-induced airway eosinophilia in rats (ED50 = 1.3 mg/kg) p.o.

PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDK' S AND GSK' S

The invention provides compounds of the formula (I), or salts, tautomers, N-oxides or solvates thereof wherein: R1 is selected from: (a) 2,6-dichlorophenyl; (b) 2,6-difluorophenyl; (c) a 2,3,6-trisubstituted phenyl group wherein the substituents for the phenyl group are selected from fluorine, chlorine, methyl and methoxy; (d) a group R0; (e) a group R a; (f) a group Rlb; (g) a group Rlc; (h) a group Rld; and 0) 2,6-difluorophenylamino ; wherein R )0υ, r R> llaa, T Rj I1bD, T R) I1cC, r R> Iidα, r R?2zaa, r R>22bD and RJ are as defined in the claims. The compounds have activity as inhibitors of cdk kinase (such as cdkl or cdk2) and glycogen synthase kinase-3 activity.